All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2018 | Phase I study of AMV564 in patients with relapsed/refractory acute myeloid leukemia

Jun 25, 2018


Data from the first-in-human phase I dose-escalation study (NCT03144245) of AMV564, a novel bivalent, bispecific CD33/CD3 targeted immunotherapy that binds both CD33 and the invariant CD3ε on T-cell receptor in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) was presented at the 23rd Congress of the European Hematology Association, Stockholm, Sweden by Peter Westervelt from Washington University School of Medicine, St. Louis, US. The main objectives of the study were to evaluate the safety, tolerability, and preliminary anti-leukemic activity of AMV564.

A total of 17 R/R AML patients (median age = 72 years, range; 24–84) have been enrolled in one of five dose escalation cohorts (three patients per cohort) including 0.5, 1.5, 5.0, 15, and 50 mcg/day for 14 days continuous infusion.

Key finding as of June 7th, 2018:

Safety

  • No dose-limiting toxicity observed
  • Most common treatment-emergent grade ≥ 3 adverse event was febrile neutropenia in 20% of patients
  • Thirty-day mortality rate: 0%

Preliminary leukemic activity observed at doses ≤ 50 mcg

  • Increased cytokine and antigen markers of T-cell activation were observed following AMV564 administration
  • Reductions in bone marrow blasts ranging from 13%–38% were observed in 10 of 16 evaluable patients
  • Two of 3 patients with progression after cycle 1 had a reduction in bone marrow blasts after cycle 2

In summary, the speaker concluded by stating that “AMV564 is well-tolerated and can be administered without the need for incremental dosing and/or pre-medication”. AMV564 also demonstrated anti-leukemic activity at low doses in patients with R/R AML.

References